All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 9 July 2019, CLR 131, an investigational small-molecule radio-therapeutic, was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)1. CLR 131 is a phospholipid drug conjugate that selectively kills cancer cells by delivering cytotoxic radiation.
The Fast Track designation was based on the positive results from a multicenter phase II clinical trial (NCT02952508) CLOVER-1, which is evaluating the efficacy and safety of CLR 131 in R/R B-cell hematologic cancers. The interim assessment of the trial showed the overall response rate of 33%2. The topline data report is expected later this year.
CLR 131 is also being evaluated in phase I studies in pediatric solid tumors and lymphoma, as well as multiple myeloma (MM)3. Earlier CLR 131 was granted Orphan Drug designation for the treatment of MM, neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma, and osteosarcoma.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox